Skip to main content
. 2020 Nov 24;109(5):1293–1303. doi: 10.1002/cpt.2091

Figure 1.

Figure 1

Clinical study design. *Cohort 5 included a pre‐treatment delayed‐type hypersensitivity challenge. Dosing with GSK2831781 occurred on day 29, hence, follow‐up is correspondingly longer relative to study day 1. ADA, anti‐drug antibodies; n, total participants (GSK2831781:placebo).